Aug 6, 2026 07:30AM
Jun 12, 2026 08:10AM
Jun 4, 2026 05:22AM
May 5, 2026 07:30AM
Apr 28, 2026 06:24AM
Apr 27, 2026 02:52PM
Apr 27, 2026 11:50AM H.C. Wainwright on Compass Therapeutics (CMPX): 'we do believe the probability of a path forward is meaningfully higher than the market reaction observed'
Apr 27, 2026 10:20AM
Apr 27, 2026 08:27AM
Apr 27, 2026 08:15AM
Apr 27, 2026 08:08AM
Apr 27, 2026 07:30AM
Apr 27, 2026 07:30AM
Mar 5, 2026 07:30AM Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update
Jan 14, 2026 10:39AM
Jan 5, 2026 04:31AM
Dec 22, 2025 07:06AM
Dec 3, 2025 03:16AM
May 8, 2025 08:00AM
Apr 1, 2025 07:01AM
Apr 1, 2025 07:00AM Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
Nov 12, 2024 08:00AM
Sep 16, 2024 06:49AM
Aug 12, 2024 08:00AM
May 13, 2024 08:00AM
Apr 25, 2024 08:00AM
Apr 16, 2024 08:00AM
Mar 21, 2024 09:00AM Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
Feb 28, 2024 08:00AM
Jan 5, 2024 08:03AM
Jan 5, 2024 08:00AM
Nov 9, 2023 07:30AM
Jun 22, 2023 04:07PM
Nov 9, 2022 04:10PM
Nov 9, 2022 09:00AM Compass Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Jul 18, 2022 07:05AM
May 16, 2022 08:00AM
May 9, 2022 08:00AM
Mar 21, 2022 08:02AM
Mar 21, 2022 08:00AM
Jan 20, 2022 08:37AM
Jan 20, 2022 08:30AM Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and
Nov 12, 2021 08:30AM
Nov 1, 2021 04:03PM

329,910 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All